We report a case of myopericytoma of the neck. A 23-year-old woman noticed a small, nontender mass in her left supraclavicular fossa. The mass had grown over a period of 5 months, prompting her to seek evaluation. On examination, no motor or sensory deficits were present. Imaging suggested that a mass had originated in the middle scalene muscle. Computed-tomography-guided core needle biopsy demonstrated a spindle-cell neoplasm with smooth-muscle differentiation. Complete surgical excision was performed. Histopathologic and immunohistochemical evaluations of the tissue sample suggested a myopericytoma. Myopericytoma is an extremely rare tumor of the head and neck. To the best of our knowledge, this is the first reported case of a myopericytoma originating in a scalene muscle.
Introduction
First described in 1998 by Granter et al, myopericytomas are rare, almost always benign, soft-tissue neoplasms. 1 They are recognized by the World Health Organization as a subset of perivascular tumors characterized by oval-to spindle-cell proliferation and myoid/myopericytic differentiation. 1 Myopericytomas reportedly occur more often in men than in women (3:2), and they present at a median age of 47 years; these tumors have been described in teenagers and octogenarians, as well. 2 A 10 to 20% recurrence rate is often cited. 3 Myopericytomas characteristically originate in cutaneous and soft tissues, but they have been described as arising from skeletal muscle, bone and, more recently, visceral organs. 2 While they are usually found in the distal extremities, they have infrequently been identified at other sites, including the head and neck and trunk. [2] [3] [4] To the best of our knowledge, no case of a myopericytoma originating in a scalene muscle has been previously reported in the literature. In this article, we describe what we believe is the first such case.
Case report
An otherwise healthy 23-year-old woman presented to our clinic for evaluation of a nontender mass in her left supraclavicular region. The mass had grown during the preceding 5 months. The patient denied pain, swelling, numbness, tingling, limitation of neck and upper-extremity range of motion, recent illness, recent weight change, fevers, or night sweats.
On physical examination, the patient's neck was soft and supple, and there was no evidence of lymphadenopathy. Her left upper extremity was warm and well perfused without evidence of edema or sensory or range-of-motion deficits. We recorded 5/5 strength and a 3+ radial pulse.
Magnetic resonance imaging (MRI) demonstrated a relatively well-circumscribed mass in the left supraclavicular fossa that measured 2.5 cm in its greatest transverse dimension. The mass was isointense to muscle on T1-weighted sequences and hyperintense on T2-weighted sequences (figure 1). It demonstrated avid but heterogeneous, predominantly peripheral enhancement. It was attached to the lateral aspect of the middle scalene muscle and was separate from the brachial plexus, which extended anteriorly and inferiorly to the mass.
Computed-tomography-guided core needle biopsy demonstrated a bland spindle-cell neoplasm with smooth-muscle differentiation. Excision of the mass was performed. Intraoperatively, the tumor was found to be densely adherent to the periosteum of the transverse processes of the spine. No direct involvement of the brachial plexus was appreciated.
Histopathologically, the lesion was nodular and well circumscribed but unencapsulated. The stroma was predominantly collagenous; a few myxoid areas were present. There was no significant necrosis. Narrow, thin-walled branching vessels were found in some areas (figure 2, A). Overall, the lesion was moderately cellular and composed of elongated eosinophilic cells with plump, smoothly demarcated, and elongated nuclei ( figure 2, B ). Mitotic figures were present but at a rate of less than 1 per 10 high-power fields.
Immunohistochemical stains (Dako EnVision; Dako North America; Carpinteria, Calif.) demonstrated immunoreactivity to smooth-muscle actin (clone 1A4). Staining for beta catenin (clone β-catenin-1) was cytoplasmic only. The tissue was negative for cytokeratin (AE1/AE3), S-100 protein (polyclonal), CD34 (clone QBEND 10), CD68 (clone PG-M1), CD117 (polyclonal), and desmin (clone V9). The tumor was diagnosed as a myopericytoma of the neck originating in the middle scalene muscle.
At 5 months postoperatively, the patient was doing well, and she showed no evidence of any motor or sensory deficits.
Discussion
First described by Zimmerman in 1923, pericytes are pluripotent stem cells that are capable of differentiating into modified smooth-muscle cells that wrap around the endothelial cells of capillaries and venules. 5 Myopericytomas are neoplasms of partially differentiated pericytic stem cells. In the differential diagnosis, myofibroma, angioleiomyoma, glomus tumor, perivascular epithelioid cell neoplasm, and hemangiopericytoma should be considered. 2 Hemangiopericytoma should be given particular consideration because (1) its vascular growth pattern is histologically similar to that of myopericytoma, and (2) this diagnosis is more often seen in the head and neck. 6 The most widely accepted method of diagnosing these rare perivascular tumors is excisional biopsy followed by histologic and immunohistochemical evaluations. Myoperictyomas are characterized by a concentric, onionskin pattern of round to ovoid eosinophilic spindle cells around vascular lumina. Immunohistochemical staining demonstrates smooth-muscle actin and h-Caldesmon positivity with myoid differentiation. A 2011 case report published by Rho et al suggested the use of an ultrasonography-guided core needle biopsy as an alternate method of diagnosis. 7 However, because of the vascular nature of this tumor, this approach may be limited to superficial tumors for which local pressure would provide sufficient hemostasis.
While almost all myopericytomas are benign, a few malignant myopericytomas have been described. 4 Their malignant nature can often be identified by the presence of active mitoses, necrosis, and nuclear atypia on histologic evaluation. A low degree of Ki-67 labeling would indicate a benign clinical course. 2 In the most common scenario of benign myopericytoma, the recurrence rate has been reported to range from 10 to 20%. 3 Recurrence is most likely attributable to either (1) the extension of cords of tumor beyond the main lesion, since it is circumscribed but not encapsulated, or (2) multifocal disease and the development of a new primary lesion secondary to field change. 3, 4 Additional risks of recurrence may include an inability to perform a wide excision because of the proximity of critical structures.
Because the number of diagnosed cases of myopericytoma is so small, management has not been well described. A definitive diagnosis is frequently not made until postexcisional laboratory evaluation. Although myopericytomas are often asymptomatic, they can present symptomatically as pain, neurologic deficits, or motor deficits. 3 Along with physical deformity, these signs and symptoms are all indications for complete surgical excision.
Initial postoperative management should include routine follow-up to assess wound healing and neurologic and motor function. In view of the risk of recurrence, surveillance examinations and imaging should be 
